Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli

NCT ID: NCT07106944

Last Updated: 2025-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-11

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In 2019, Indonesia's first WHO Tricycle Project revealed alarming rates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli across various sectors. The study found ESBL-producing E. coli in 40% of pregnant women, 57.7% of E. coli-induced bloodstream infections, 67.1% of broiler chicken, and 12.8% of total E. coli in water samples. In the first National Action Plan on Antimicrobial Resistance from Indonesia, the reduction of ESBL was identified as a clear goal. In E-Trike, Tricycle will be repeated, using the same methodology, to determine if a reduction has been achieved. Additionally, ESBL-positive Klebsiella pneumoniae will be included, as important pathogen for humans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Antimicrobial resistance (AMR) is a global threat and is considered to be a silent pandemic. It is estimated that in 2021, over 4.71 million deaths were associated with AMR, with 1.14 million attributed to AMR. In 2020, the World Health Organization (WHO) Global Antimicrobial Resistance and Use Surveillance System (GLASS) reported the prevalence of cefotaxime-, ceftriaxone, and ceftazidime-resistant Klebsiella pneumoniae from bloodstream infections in South Asian region was 75.9%, 77.4%, 74.8%, respectively. Based on the report from the Indonesian Society for Clinical Microbiologists in 2023, the prevalence of third-generation cephalosporin-resistant Klebsiella pneumoniae in Indonesia was 57%, while third-generation cephalosporin-resistant E. coli was 68%.

The WHO has been at the forefront of AMR through its Global Surveillance extended-spectrum beta-lactamase (ESBL)-positive E. coli Tricycle Project, which employs a "One Health" approach. This innovative surveillance program aims to obtain a comprehensive picture of AMR in humans, animals, and the environment, particularly in countries with limited surveillance capabilities. Indonesia's first pilot Tricycle Project revealed alarming rates of ESBL-producing E. coli across various sectors. The study found ESBL-producing E. coli in 40% of pregnant women, 57.7% of E. coli-induced bloodstream infections, 67.1% of broiler chicken, and 12.8% of total E. coli in water samples. These findings underscore the worrisome pattern of AMR in Indonesia and highlight the urgent need for expanded surveillance and control strategies.

Klebsiella pneumoniae is the second most common Enterobacterales found in humans; its role in animals and the environment is less clear, even more in the Indonesian setting. A better understanding of the presence of this human pathogen in other domains is needed, so that effective intervention strategies on AMR for the Indonesian situation can be designed.

In E-Trike, the original WHO Tricycle protocol (which already includes sample size calculation) will be used, with three modifications:

1. ESBL-K. pneumoniae (ESBL-Kp) will be included for all samples. Additionally, from pregnant women, not only rectal samples will be taken, but also throat samples, as previously it was shown that 15% of adults carry Kp in their throat in Indonesia.
2. In addition to the MacConkey agar supplemented with cefotaxime, CHROMagar plates will be used.
3. The sampling period will only be 5 months, instead of the 10 months that was used in the 2019 Tricycle. However, both "wet" and "dry" months will be included.

Primary aims:

* To determine the prevalence of ESBL-producing E. coli (ESBL-Ec) in humans (hospital and community), the food chain (animals), and the environment.
* To determine the prevalence of ESBL-producing Klebsiella pneumoniae (ESBL-Kp) in humans (hospital and community), the food chain (animals), and the environment.

Secondary aims:

* To compare the yield of the ESBL Chromagar™ plate compared to the MacConkey agar plate supplemented with 4 mg/L cefotaxime.
* To assess the susceptibility of the ESBL-Ec and ESBL-Kp to carbapenem antibiotics and other relevant classes of antibiotic.
* To understand the resistance mechanisms of ESBL-Ec and ESBL-Kp isolates using genomic analysis.

Setting The study will be performed in Jakarta, Indonesia.

Surveillance in humans will include:

Community: rectal and throat carriage in pregnant women in 3 puskesmas. From Hospitals: bloodstream infections with E. coli and K. pneumoniae, Cipto Mangunkusumo Hospital and Persahabatan Hospital; isolates will be included

Surveillance in food chain will include:

Chicken caeca from the live bird open market and slaughterhouse in Jakarta

Surveillance in the environment will include:

River water upstream and downstream, animal slaughter wastewater, human communal wastewater

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carriage of ESBL-positive Escherichia Coli Carriage of ESBL-positive Klebsiella Pneumoniae

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Community pregnant women

Pregnant women who do antenatal visits in primary health care centre (Puskesmas) located around Cipto Mangunkusumo Hospital, Persahabatan Hospital and Sulianti Saroso Hospital; Puskesmas Johar Baru, Puskesmas Pulogadung, and Puskesmas Koja. After informed consent, a rectal swab and throat swab will be taken. Basic demographic data will be recorded.

Community pregnant women: rectal and throat swab

Intervention Type OTHER

Community pregnant women: rectal and throat swab

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Community pregnant women: rectal and throat swab

Community pregnant women: rectal and throat swab

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pregnant women at antenatal visits

Exclusion Criteria

* no informed consent
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr. Sulianti Saroso Hospital, Jakarta

UNKNOWN

Sponsor Role collaborator

Universitas Indonesia, Cipto Mangunkusumo National General Hospital

UNKNOWN

Sponsor Role collaborator

RSUP Persahabatan Hospital, Jakarta, Indonesia

UNKNOWN

Sponsor Role collaborator

National Institute for Public Health and the Environment (RIVM)

OTHER_GOV

Sponsor Role collaborator

Utrecht University

OTHER

Sponsor Role collaborator

Erasmus Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Juliëtte Severin

Associate professor, MD PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Juliëtte A. Severin, MD PhD

Role: CONTACT

References

Explore related publications, articles, or registry entries linked to this study.

Puspandari N, Sunarno S, Febrianti T, Febriyana D, Saraswati RD, Rooslamiati I, Amalia N, Nursofiah S, Hartoyo Y, Herna H, Mursinah M, Muna F, Aini N, Risniati Y, Dhewantara PW, Allamanda P, Wicaksana DN, Sukoco R, Efadeswarni, Nelwan EJ, Cahyarini, Haryanto B, Sihombing B, Soares Magalhaes RJ, Kakkar M, Setiawaty V, Matheu J. Extended spectrum beta-lactamase-producing Escherichia coli surveillance in the human, food chain, and environment sectors: Tricycle project (pilot) in Indonesia. One Health. 2021 Sep 23;13:100331. doi: 10.1016/j.onehlt.2021.100331. eCollection 2021 Dec.

Reference Type BACKGROUND
PMID: 34632041 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-Trike

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Antibiotics on Urinary Microbiome
NCT04230746 WITHDRAWN EARLY_PHASE1